The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†
Abstract
UNLABELLED: In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using UDCA (13-15 mg/kg/day) was unable to confirm these results. Accordingly, a randomized, placebo-controlled study was initiated with a high dose of UDCA (23-28 mg/kg/day). The allocation of patients and the evaluation of liver histology were performed according to a modified Brunt score and the nonalcoholic fatty liver disease activity score (NAS). With the modified Brunt score, 185 patients with histologically proven NASH were randomized [intention to treat (ITT)], and 147 were treated per protocol (PP). With the NAS, 137 patients were confirmed to have NASH, 48 had borderline NASH, and 1 did not have NASH. The treatment time was 18 months. At entry, the treatment groups were comparable. A second biopsy sample was obtained from 139 of 185 patients (NAS: 107/137). The primary criterion for evaluation was a change in the liver histology; the secondary criteria were single histological variables and liver biochemistry. Significant differences in the overall histology could not be detected between the two treatment groups with the modified Brunt score (P = 0.881) or NAS (P = 0.355). Only lobular inflammation improved significantly (P for the modified Brunt score = 0.011, P for NAS = 0.005). In subgroup analyses, significant improvements in lobular inflammation were also observed in males, younger patients up to 50 years of age, slightly overweight patients, and patients with hypertension and an increased histology score. The fibrosis score did not change (P for ITT = 0.133, P for PP = 0.140). With the exception of gamma-glutamyl transferase, UDCA did not improve laboratory data. CONCLUSION: High-dose UDCA failed to improve the overall histology in patients with NASH in comparison with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are three larger, placebo-controlled trials of UDCA in MASH differing in the dose of UDCA used 373 -375 and only two of them report histological endpoints.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [374]
In the citing paper
“Despite several limitations and methodological differences, there is a strong indication of biochemical effi cacy (ALT reduction) and a good safety pro fi le, but no proof of histological ef fi cacy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [374]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Osei‐Hyiaman, D., DePetrillo, M. A., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J. D., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23057 · Cited by 1,131
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Adams, L. A., Sanderson, S. O., Lindor, K. D., & Angulo, P. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 912
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
Harrison, S. A., Torgerson, S., Hayashi, P. H., Ward, J. A., & Schenker, S. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.08699.x · Cited by 728
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Crespo, J., Cayón, A., Fernández-Gil, P. L., Hernández‐Guerra, M., Mayorga, M., Domínguez‐Díez, A., Fernández-Escalante, J. C., & Pons‐Romero, F. (2001) · Hepatology · doi:10.1053/jhep.2001.29628 · Cited by 708
Laurin, J. M., Lindor, K., Crippin, J. S., Gossard, A. A., Gores, G. J., Ludwig, J., Rakela, J. L., & McGill, D. B. (1996) · Hepatology · doi:10.1002/hep.510230624 · Cited by 565
Hepatic effects of dietary weight loss in morbidly obese subjects
Andersen, T., Gluud, C. N., Franzmann, M., & Christoffersen, P. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90942-5 · Cited by 405
Dufour, J., Oneta, C. M., Gonvers, J., Bihl, F. K., Cerny, A., Cereda, J., Zala, J., Helbling, B., Steuerwald, M., & Zimmermann, A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.025 · Cited by 360
Merriman, R. B., Ferrell, L. D., Patti, M. G., Weston, S. R., Pabst, M. S., Aouizerat, B. E., & Bass, N. M. (2006) · Hepatology · doi:10.1002/hep.21346 · Cited by 325
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L. A., & Vettor, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01821 · Cited by 266
Hirschfield, G. M., & Heathcote, E. J. (2010) · Wiley eBooks · doi:10.1002/9781444314403.ch32 · Cited by 261
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
Lutchman, G. A., Modi, A. A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M. G., Borg, B. B., Loomba, R. S., Liang, T. J., Premkumar, A., et al. (2007) · Hepatology · doi:10.1002/hep.21661 · Cited by 240
Angulo, P. (2010) · Hepatology · doi:10.1002/hep.23521 · Cited by 232
Betaine for nonalcoholic fatty liver disease
Abdelmalek, M. F., Sanderson, S. O., Angulo, P., Soldevila‐Pico, C., Liu, C., Peter, J. A., Keach, J. C., Cave, M. C., Chen, T., McClain, C. J., et al. (2009) · Hepatology · doi:10.1002/hep.23239 · Cited by 225
Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis
Kıyıcı, M., Gülten, M., Gürel, S., Nak, S. G., Dolar, E., Savcı, G., Adım, Ş. B., Yerci, Ö., & Memik, F. (2003) · Canadian Journal of Gastroenterology · doi:10.1155/2003/857869 · Cited by 200
Satapathy, S. K., Garg, S., Chauhan, R., Sakhuja, P., Malhotra, V., Sharma, B. C., & Sarin, S. K. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40220.x · Cited by 198
Neuman, M. G., Angulo, P., Malkiewicz, I. M., Jorgensen, R. A., Shear, N. H., Dickson, E. R., Haber, J. A., Katz, G. G., & Lindor, K. D. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02672.x · Cited by 142
Merat, S., Malekzadeh, R., Sohrabi, M., Sotoudeh, M., Rakhshani, N., Sohrabpour, A. A., & Nasseri‐Moghaddam, S. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00441-5 · Cited by 126
4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells
Zamara, E., Novo, E., Marra, F., Gentilini, A., Romanelli, R. G., Caligiuri, A., Robino, G., Tamagno, E., Aragno, M., Danni, O., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00480-x · Cited by 123
Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis
Toshio, F., Fukushima, J., Shiga, J., Takahashi, Y., NAKANO, T., Maeyama, S., Masayuki, U., Ohbu, M., Matsumoto, T., & Matsumoto, K. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.09.018 · Cited by 74
Bellentani, S. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200502000-00001 · Cited by 47
Angulo, P. G. (2010) · Hepatology · doi:10.1002/hep.23677 · Cited by 13
Ratziu, V., de Lédinghen, V., Oberti, F., Mathurin, P., Wartelle‐Bladou, C., Renou, C., & Spénard, J. (2009) · Journal of Hepatology · doi:10.1016/s0168-8278(09)60049-0 · Cited by 7
Research works printed but not linked: 1
- Padda, 1999, The effect of ursodeoxycholic acid (UDCA) treatment on liver tests in patients with non alcohol induced steatohepatitis (NASH), Am J Gastroenterol, 94, A334
Cited by
Sorted by citations
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,859
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Metadata
- Authors
- Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T.
- Affiliations
- Krankenhaus Sachsenhausen (DE)
- Goethe University Frankfurt (DE)
- Klinikum Ludwigsburg (DE)
- Agaplesion Diakonieklinikum Rotenburg (DE)
- University Hospital Leipzig (DE)
- Corresponding author
- Leuschner, Ulrich F. H.
- Venue
- Hepatology
- Published
- 2010-08
- Volume
- 52
- Issue
- 2
- Pages
- 472-479
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2097677758
- Cited by
- 317
- References
- 36
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 15 · 2021: 29 · 2020: 17 · 2019: 25 · 2018: 15 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 23 · 2013: 25 · 2012: 25
- FWCI
- 19.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- ursodeoxycholic acid, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver histopathology, lobular inflammation, liver fibrosis, liver biochemistry, gamma-glutamyl transferase
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Fatty Liver, Female, Humans, Male, Middle Aged, Ursodeoxycholic Acid, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
